Background: Finding patients at risk of developing contrast-induced acute kidney injury (CI-AKI) is important because of its associated complications. In the present study, the contribution of different variables, such as the presence of metabolic syndrome (MetS), the volume creatinine clearance (V/CrCl) ratio, the iodine-dose (I-dose)/CrCl ratio, or hypertension, to CI-AKI was evaluated. Methods: A total of 255 patients undergoing elective coronary angiography with or without intervention were enrolled and divided into a MetS and a control group. All patients were assessed for the development of CI-AKI after the procedures. Results: CI-AKI occurred in 39.23% (51 of 130) of the MetS patients and 14.4% (18 of 125) of the control group (p < 0.001). The multivariable regression model showed that male sex and the use of statins decreased the risk of CI-AKI, and high triglyceride levels, I-dose/CrCl > 0.52, MetS, CrCl ≤60 mL/min, and age ≥70 years increased the risk of CI-AKI, independent of confounding factors. The difference in the mean V/CrCl ratio was statistically significant between patients who developed CI-AKI and those who did not show renal impairment (2.36 ± 1.35 vs. 1.43 ± 0.89, respectively; p < 0.001). The ROC curve analysis of I-dose/CrCl determined the best cutoff value for patients with and those without MetS as 0.51 and 0.63, with a sensitivity value of 68 and 72% and a specificity value of 73 and 74%, respectively. Conclusions: We showed that MetS is a strong risk factor for CI-AKI in nondiabetic patients undergoing elective coronary interventions; and the I-dose/CrCl ratio is a strong predictor of CI-AKI in these patients. We suggest that clinicians identify MetS patients and calculate their I-dose/CrCl ratio before coronary interventions.

Keywords:
Metabolic syndrome, Contrast-induced nephropathy, Creatinine clearance
1.
McCullough P: Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention. Catheter Cardiovasc Interv 2006; 67: 335–343.
2.
Thomsen HS: Management of acute adverse reactions to contrast media, in Thomsen H, Webb J (eds): Contrast Media. Medical Radiology. Berlin, Springer, 2014, pp 63–69.
3.
Gleeson TG, Bulugahapitiya S: Contrast-induced nephropathy. AJR Am J Roentgenol 2004; 183: 1673–1689.
4.
Toprak O, Cirit M, Yesil M, Byrne DW, Postaci N, Bayata S, Majchrzak KM, Esi E: Metabolic syndrome as a risk factor for contrast-induced nephropathy in non-diabetic elderly patients with renal impairment. Kidney Blood Press Res 2006; 29: 2–9.
5.
Kashif W, Khawaja A, Yaqub S, Hussain SA: Clinically significant contrast induced acute kidney injury after non-emergent cardiac catheterization – risk factors and impact on length of hospital stay. J Coll Physicians Surg Pak 2013; 23: 842–847.
6.
Mehran R, Nikolsky E: Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006; 69:S11–S15.
7.
Wickenbrock I, Perings C, Maagh P, Quack I, van Bracht M, Prull MW, Plehn G, Trappe HJ, Meissner A: Contrast medium induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI. Clin Res Cardiol 2009; 98: 765–772.
8.
Dussol B, Morange S, Loundoun A, Auquier P, Berland Y: A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 2006; 21: 2120–2126.
9.
Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005; 365: 1415–1428.
10.
Kumar PA, Chitra PS, Reddy GB: Metabolic syndrome and associated chronic kidney diseases: nutritional interventions. Rev Endocr Metab Disord 2013; 14: 273–286.
11.
Ozcan OU, Adanir Er H, Gulec S, Ustun EE, Gerede DM, Goksuluk H, Tulunay Kaya C, Erol C: Impact of metabolic syndrome on development of contrast-induced nephropathy after elective percutaneous coronary intervention among nondiabetic patients. Clin Cardiol 2015; 38: 150–156.
12.
Worasuwannarak S, Pornratanarangsi S: Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio. J Med Assoc Thai 2010; 93(suppl 1):S29–S34.
13.
Laskey WK, Jenkins C, Selzer F, Marroquin OC, Wilensky RL, Glaser R, Cohen HA, Holmes DR Jr; NHLBI Dynamic Registry Investigators: Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol 2007; 50: 584–590.
14.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
15.
Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393–1399.
16.
Wi J, Ko YG, Shin DH, Kim JS, Kim BK, Choi D, Ha JW, Hong MK, Jang Y: Prediction of contrast-induced nephropathy with persistent renal dysfunction and adverse long-term outcomes in patients with acute myocardial infarction using the Mehran Risk Score. Clin Cardiol 2013; 36: 46–53.
17.
McCullough PA: Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51: 1419–1428.
18.
Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, Grines CL, O’Neill WW: Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004; 93: 1515–1519.
19.
Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259–2264.
20.
McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, Tumlin J; CIN Consensus Working Panel: Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006; 98: 27–36.
21.
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW: Chronic kidney disease: global dimension and perspectives. Lancet 2013; 382: 260–272.
22.
Toprak O, Cirit M, Yesil M, Bayata S, Tanrisev M, Varol U, Ersoy R, Esi E: Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. Nephrol Dial Transplant 2007; 22: 819–826.
23.
McCullough PA, Soman SS: Contrast-induced nephropathy. Crit Care Clin 2005; 21: 261–280.
24.
Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M, Mintz GS, Kent KM, Pichard AD, Satler LF, Stone GW, Leon MB: Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 2003; 15: 18–22.
25.
Omran J, Al-Dadah A, Dellsperger KC: Dyslipidemia in patients with chronic and end-stage kidney disease. Cardiorenal Med 2013; 3: 165–177.
26.
Chanin JM, Yang DC, Haider MA, Swaminathan RV, Kim LK, Charitakis K, Tanoue M, Minutello RM, Gade CL, Singh HS, Bergman G, Wong SC, Feldman DN: Impact of chronic statin therapy on postprocedural contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention. J Invasive Cardiol 2015; 27: 490–496.
27.
Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F: Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol 2014; 63: 71–79.
28.
Liang M, Yang S, Fu N: Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: a meta-analysis of 15 randomized controlled trials. Medicine (Baltimore) 2017; 96:e7384.
29.
Nyman U, Almén T, Aspelin P, Hellström M, Kristiansson M, Sterner G: Contrast-medium-induced nephropathy correlated to the ratio between dose in gram iodine and estimated GFR in ml/min. Acta Radiol 2005; 46: 830–842.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.